cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Geron Corporation
35 own
47 watching
Current Price
$4.87
$-0.01
(-0.2%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,077.89M
52-Week High
52-Week High
5.34000
52-Week Low
52-Week Low
1.64000
Average Volume
Average Volume
11.44M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,077.89M
icon52-Week High5.34000
icon52-Week Low1.64000
iconAverage Volume11.44M
iconDividend Yield--
iconP/E Ratio--
What does the Geron Corporation do?
Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of a telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.
Read More
How much money does Geron Corporation make?
News & Events about Geron Corporation.
Business Wire
11 months ago
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that an Expanded Access Protocol (EAP) is available for imetelstat, the Companys first-in-class telomerase inhibitor. As allowed under the U.S. Food and Drug Administration (FDA) policies, companies...
Zolmax
11 months ago
Geron (NASDAQ:GERN Get Rating) and Theseus Pharmaceuticals (NASDAQ:THRX Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, ...
Business Wire
12 months ago
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the submission to the United States Food and Drug Administration (FDA) of a New Drug Application (NDA) for imetelstat for the treatment of transfusion-dependent anemia in adult patients with low- to...
Business Wire
1 year ago
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the first patient has been dosed in the investigator-led Phase 2 IMpress clinical trial evaluating imetelstat, the Companys first-in-class telomerase inhibitor, in patients with acute myeloid...
Business Wire
1 year ago
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced new data and analyses from IMerge Phase 3 reporting robust durability of transfusion independence (TI), evidence for disease-modifying activity and favorable fatigue patient-reported outcomes (PRO) in...
Frequently Asked Questions
Frequently Asked Questions
What is Geron Corporation share price today?
plus_minus_icon
Can Indians buy Geron Corporation shares?
plus_minus_icon
How can I buy Geron Corporation shares from India?
plus_minus_icon
Can Fractional shares of Geron Corporation be purchased?
plus_minus_icon
What are the documents required to start investing in Geron Corporation stocks?
plus_minus_icon
What is today’s traded volume of Geron Corporation?
plus_minus_icon
What is today’s market capitalisation of Geron Corporation?
plus_minus_icon
What is the 52-Week High and Low Range of Geron Corporation?
plus_minus_icon
What percentage is Geron Corporation down from its 52-Week High?
plus_minus_icon
What percentage is Geron Corporation up from its 52-Week Low?
plus_minus_icon
Current Price
$4.87
$-0.01
(-0.2%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00